symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
SPRY,3.67,0,1235659,350735676,0,2.55-9.65,0.01,"ARS Pharmaceuticals, Inc.",USD,0001671858,,,NASDAQ Global Market,NASDAQ,Biotechnology,https://ars-pharma.com,"ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.","Mr. Richard  Lowenthal M.B.A., M.S., MSMSEL",Healthcare,US,29,858 335 1300,3525 Del Mar Heights Road,San Diego,CA,92130,,0,https://financialmodelingprep.com/image-stock/SPRY.png,2020-12-04,False,False,True,False,False
